Treatment of hemophagocytic lymphohistiocytosis in the era of new biologics
- 1 October 2020
- journal article
- editorial
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (10), e28631
- https://doi.org/10.1002/pbc.28631
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapiesSeminars in Arthritis and Rheumatism, 2016
- Therapeutic Role of Anakinra, an Interleukin-1 Receptor Antagonist, in the Management of Secondary Hemophagocytic Lymphohistiocytosis/Sepsis/Multiple Organ Dysfunction/Macrophage Activating Syndrome in Critically Ill Children*Pediatric Critical Care Medicine, 2014
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyBlood, 2013
- Treatment of Epstein Barr virus‐induced haemophagocytic lymphohistiocytosis with rituximab‐containing chemo‐immunotherapeutic regimensBritish Journal of Haematology, 2013
- Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumabPediatric Blood & Cancer, 2012
- Etanercept for therapy‐resistant macrophage activation syndromePediatric Blood & Cancer, 2006
- Macrophage activation syndrome in juvenile idiopathic arthritisActa Paediatrica, 2006
- Macrophage activation syndrome in juvenile idiopathic arthritisActa Paediatrica, 2006
- Success with infliximab in treating refractory hemophagocytic lymphohistiocytosisAmerican Journal of Hematology, 2005
- An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorderBlood, 2004